Endothelial Function in Young Hispanic Adults at Risk for Type 2 Diabetes
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Obesity
- Sponsor
- Joslin Diabetes Center
- Enrollment
- 44
- Locations
- 1
- Primary Endpoint
- markers of endothelial activation, coagulation and inflammation
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
Diabetes is a major public health problem. Hispanics/Latinos are known to be at higher risk for type 2 diabetes. The function of the endothelium has played a key role in the understanding of vascular complications in people with diabetes. Endothelial function and vascular reactivity are impaired not only in white adults with type 2 diabetes but also in those at risk for the disease by virtue of having impaired glucose tolerance or parental history of type 2 diabetes. Whether this finding is applicable to hispanics is not known. The investigators plan to assess the endothelial function and vascular reactivity in young Hispanic adults at risk of developing type 2 diabetes by virtue of being obese and belonging to a minority population.
Investigators
Enrique Caballero
Clinical Investigator/Director, Latino Diabetes Initiative
Joslin Diabetes Center
Eligibility Criteria
Inclusion Criteria
- •Age between 18-40 years;
- •Hispanic (we will consider a subject being Hispanic if both parents are reported as Hispanics when asked the following question: "What ethnic group do you consider that you belong to?");
- •History of type 2 diabetes in one or both parents;
- •BMI above 27;
- •Not have participated in any exercise program for the 6 months prior to the beginning of the study.
- •Age between 18-40 years;
- •Hispanic (same criteria as above );
- •No history of type 2 diabetes in any first degree relative;
- •BMI under 25;
- •Not have participated in any exercise program for the 6 months prior to the beginning of the study.
Exclusion Criteria
- •diabetes, glucose intolerance, pregnancy, smoking, cardiovascular disease, uncontrolled hypertension, renal disease, proteinuria, cancer, infectious diseases, severe GI diseases, lung disease, electrolyte abnormalities, anemia, endocrine disorders, severe dyslipidemia, peripheral vascular disease, medications: beta-blockers, any diuretic, calcium channel blockers, ACE inhibitors, angiotensin receptor blockers, niacin, glucocorticoids, any antineoplastic agent, antibiotics, psychoactive agents, bronchodilators or insulin.
Outcomes
Primary Outcomes
markers of endothelial activation, coagulation and inflammation
Time Frame: cross sectional evaluation